Comparison of athletic performance of Turkish ice hockey players with ACE I/D (rs1799752), ACTN3 (rs1815739), PPARA (rs4253778) and HIF1A (rs11549465) polymorphisms
- PMID: 39605112
- DOI: 10.14715/cmb/2024.70.10.19
Comparison of athletic performance of Turkish ice hockey players with ACE I/D (rs1799752), ACTN3 (rs1815739), PPARA (rs4253778) and HIF1A (rs11549465) polymorphisms
Abstract
Our study is aimed at examining the Ice Hockey National Team players with regard to ACE I/D (rs1799752), ACTN3 (rs1815739), PPARA (rs4253778) and HIF1A (rs11549465) polymorphisms and physical tests. This study was participated by 21 players from ice hockey national team. While ACE I/D (rs1799752) polymorphism was obtained using conventional polymerase chain reaction method (PCR), ACTN3 (rs1815739), PPARA (rs4253778) and HIF1A (rs11549465) polymorphisms were produced by real time polymerase chain reaction method (qPCR). Athletic performance analysis, on the other hand, was based on the assessment of maximal oxygen consumption capacity (VO2max), anaerobic performance, flexibility and strength tests. In our cohort, ACE I/D (rs1799752) polymorphism was determined as 24% genotype II, 33% genotype ID, and 43% genotype DD. ACTN3 (rs1815739) polymorphism was determined as 24% genotype RR, 43% genotype RX, and 33% genotype XX. PPARA (rs4253778) polymorphism was observed as 71% genotype GG, 14.5% genotype GC, 14.5% genotype CC. HIF1A (rs11549465) polymorphism was found to be 67% genotype CC, 33% genotype CT. Concerning physical tests, the evaluation of flexibility test results among genotype groups did not yield significant differences (p=0.365). No significant difference was found among genotype groups with respect to leg strength test results (p=0.691). The evaluation of handgrip strength test results among genotype groups did not reveal significant differences (p=0.679). No significant differences were found among genotype groups when VO2 max test results were examined (p=0.686). A significant relationship was found in the speed test and HIF1A rs11549465 polymorphism evaluation (p = 0.008). No significant results were detected when comparing the speed test with other polymorphisms (p = 0.65). The results of our study support the previous studies which had focused on the potential relation between the relevant gene polymorphisms and athletic performance of ice hockey players. However, doing further studies with larger cohorts is recommended in order to understand the relationship between the relevant polymorphisms and athletic performance of ice hockey players.
Similar articles
-
Changes in Vertical Jump Parameters After Training Unit in Relation to ACE, ACTN3, PPARA, HIF1A, and AMPD1 Gene Polymorphisms in Volleyball and Basketball Players.Genes (Basel). 2025 Feb 21;16(3):250. doi: 10.3390/genes16030250. Genes (Basel). 2025. PMID: 40149402 Free PMC article.
-
The relationships between ACTN3 rs1815739 and PPARA-α rs4253778 gene polymorphisms and athletic performance characteristics in professional soccer players.BMC Sports Sci Med Rehabil. 2023 Sep 25;15(1):121. doi: 10.1186/s13102-023-00733-0. BMC Sports Sci Med Rehabil. 2023. PMID: 37749582 Free PMC article.
-
The Determination Of The Relationship Between Vo2max And The Angiotensin-Converting Enzyme Gene (ACE) rs1799752 Polymorphisms In The Turkish National Ice Hockey Sports Team.Cell Mol Biol (Noisy-le-grand). 2022 Sep 30;68(10):90-93. doi: 10.14715/cmb/2022.68.10.14. Cell Mol Biol (Noisy-le-grand). 2022. PMID: 37114266
-
Genes for elite power and sprint performance: ACTN3 leads the way.Sports Med. 2013 Sep;43(9):803-17. doi: 10.1007/s40279-013-0059-4. Sports Med. 2013. PMID: 23681449 Review.
-
The association of the ACTN3 R577X and ACE I/D polymorphisms with athlete status in football: a systematic review and meta-analysis.J Sports Sci. 2021 Jan;39(2):200-211. doi: 10.1080/02640414.2020.1812195. Epub 2020 Aug 28. J Sports Sci. 2021. PMID: 32856541
Cited by
-
Dissolving Microneedles Containing Lactoferrin Nanosuspension for Enhancement of Antimicrobial and Anti-Inflammatory Effects in the Treatment of Dry Eye Disease.Pharmaceutics. 2025 May 16;17(5):653. doi: 10.3390/pharmaceutics17050653. Pharmaceutics. 2025. PMID: 40430943 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Miscellaneous